Glaxo bonds bring whopping $9B

GlaxoSmithKline went hat in hand to the bond markets and came back with a record $9 billion. Intending to sell $6 billion in corporate bonds, GSK added $3 billion more as investors hungry for non-financial corporate issues snapped up the offerings.

GSK plans to use the proceeds for its big share buy-back plan. That plan is designed to strengthen GSK stock at a time when the entire pharma sector is suffering on the equity markets.

- read the story in the Financial Times

ALSO: In Vivo is reporting that GlaxoSmithKline plans to set aside up to $500 million for a new venture fund that will support its internal R&D work as well as fund start-ups created from de-prioritized assets. GSK report

Related Articles:
Best and Worst Pharma stocks of 2007
Big Biotech emerges as a shelter in economic storm
Big Biotech's Stock Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.